The use of cannabis compounds for pharmacotherapy of Gilles de la Tourette’s Disease
Abstract
Objective: to analyze the medicinal relationship between Cannabis and Tourette's Syndrome. Methods: this integrative literature review used the PubMed, LILACS, MedLine, SciELO, and Science Direct databases to filter articles published in the last 5 years in english, portuguese, or spanish that focus on the use of these compounds for the disorder. Results: the treatment's effectiveness varies according to dosage and administration method, with common mild side effects like sedation, dry mouth, and dizziness, pointing to challenges in standardizing and homogenizing treatments in new evidence. Conclusion: Despite promising results, findings are still inconclusive and insufficient to support clinical recommendations, and further studies with robust methodologies and larger samples are needed to confirm the efficacy of Cannabis in treating this disorder.
Downloads
References
Maiola R. Georges Gilles de la Tourette. Medicina (B Aires). 2022;82(3):459–60.
American Psychiatric Association. DSM-5: Manual diagnóstico e estatístico de transtornos mentais. Porto Alegre: Artmed; 2014.
Nieto-Pico AM, Rueda-Vargas A, Mora-Bautista VM. Trastornos por tics en niños: un caso con retraso diagnóstico. Ces Med. 2019;33(2):126–33.
Fernández S, Larraguibel Q. Síndrome de Tourette: Tratamiento farmacológico en pacientes pediátricos, una puesta al día. Rev Chil Psiquiatr Neurol Infanc Adolesc. 2020;31(2):91–104.
Anis S, Davidov A, Ben‐Ari Y, Pellegrino G, Snir Y, Goldstein M, et al. Medical Cannabis for Gilles de la Tourette syndrome: An open‐label prospective study. Behav Neurol. 2022;2022:5141773.
Dyke K, Naros G, Hidding U, Rogalewski A, Bäumer T, Dresel C, et al. Effects of single-session cathodal transcranial direct current stimulation on tic symptoms in Tourette's syndrome. Exp Brain Res. 2019;237(11):2853–63.
Singer HS, Augustine F. Controversies surrounding the pathophysiology of tics. J Child Neurol. 2019;34(13):851–62.
Roessner V, Hoekstra PJ, Rizzo R, Stern JS, Mathews CA, Porta M, et al. European clinical guidelines for Tourette syndrome and other tic disorders—version 2.0. Part III: pharmacological treatment. Eur Child Adolesc Psychiatry. 2022;31(3):403–20.
Müller-Vahl KR, Roessner V, Rizzo R, Jakubovski E, Stern JS, Hoekstra PJ, et al. European clinical guidelines for Tourette syndrome and other tic disorders: summary statement. Eur Child Adolesc Psychiatry. 2022;31(3):377–82.
Groh CJ. Medical Cannabis and psychiatric disorders: Implications for psychiatric nurses. J Am Psychiatr Nurses Assoc. 2022;28(1):91–103.
Szejko N, Jakubovski E, Müller-Vahl KR. Cannabis-based medicine in treatment of patients with Gilles de la Tourette syndrome. Neurol Neurochir Pol. 2022;56(1):28–38.
Brasil. Conselho Federal de Medicina. Resolução CFM nº 2.324, de 11 de outubro de 2022. Diário Oficial da União, Brasília, DF; 2022 Oct 14.
Efron D, Taylor K. Medicinal Cannabis for paediatric developmental, behavioural and mental health disorders. Int J Environ Res Public Health. 2023;20(8):5430.
Hoch E, Niemann D, von Keller R, Schneider M, Friemel CM, Preuss UW, et al. How effective and safe is medical Cannabis as a treatment of mental disorders? A systematic review. Eur Arch Psychiatry Clin Neurosci. 2019;269:87–105.
Klumpers LE, Thacker DL. A brief background on Cannabis: From plant to medical indications. J AOAC Int. 2019;102(2):412–20.
Bloch MH, Panza KE, Landeros-Weisenberger A, Brennan BD, Leckman JF, Pittenger C. A phase-2 pilot study of a therapeutic combination of Δ9-tetrahydracannabinol and palmitoylethanolamide for adults with Tourette’s syndrome. J Neuropsychiatry Clin Neurosci. 2021;33(4):328–36.
Müller-Vahl KR. Cannabinoids in the treatment of selected mental illnesses: Practical approach and overview of the literature. Pharmacopsychiatry. 2024;57(1):14–23.
Schwittay MA, Steinbrecher A, Lobsien E. Tic reduction in adult onset Gilles De La Tourette syndrome using as required Nabiximols spray. Tremor Other Hyperkinet Mov. 2021;11:30.
Aran A, Cayam-Rand D. Medical Cannabis in children. Rambam Maimonides Med J. 2020;11(1):e0002.
Müller-Vahl KR, Pisarenko A, Jakubovski E, Fremer C, Schürmann M, Kolbe H, et al. Endocannabinoid modulation using monoacylglycerol lipase inhibition in Tourette syndrome: a phase 1 randomized, placebo-controlled study. Pharmacopsychiatry. 2022;55(3):148–56.
Müller-Vahl KR, Jakubovski E, Schürmann M, Kolbe H, Davies P, Pisarenko A, et al. CANNA-TICS: Efficacy and safety of oral treatment with nabiximols in adults with chronic tic disorders – Results of a prospective, multicenter, randomized, double-blind, placebo-controlled, phase IIIb superiority study. Psychiatry Res. 2023;323:115135.
Serag I, ElSayed M, Abdelrahman S, Elbarbary M. Efficacy of Cannabis-based medicine in the treatment of Tourette syndrome: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2024;80(10):1483–93.
Müller-Vahl KR, Jakubovski E, Pisarenko A, Fremer C, Kolbe H, Schürmann M, et al. Monoacylglycerol lipase inhibition in Tourette syndrome: a 12-week, randomized, controlled study. Mov Disord. 2021;36(10):2413–8.
Jakubovski E, Martino D, Müller-Vahl KR. The CANNA-TICS study protocol: a randomized multi-center double-blind placebo controlled trial to demonstrate the efficacy and safety of nabiximols in the treatment of adults with chronic tic disorders. Front Psychiatry. 2020;11:575826.
Mosley PE, Herbert A, Malpas G, Dwyer J, Martin JH. Tetrahydrocannabinol and cannabidiol in Tourette syndrome. NEJM Evid. 2023;2(9):EVIDoa2300012.
Lasch F, Trottmann M, Goetz S, Jakubovski E, Müller-Vahl KR. Potential impact of COVID‐19 on ongoing clinical trials: a simulation study with the neurological Yale Global Tic Severity Scale based on the CANNA‐TICS study. Pharm Stat. 2021;20(3):675–91.
Szejko N, Roessner V, Rizzo R, Jakubovski E, Hoekstra PJ, Müller-Vahl KR. European clinical guidelines for Tourette syndrome and other tic disorders—version 2.0. Part I: assessment. Eur Child Adolesc Psychiatry. 2022;31(3):383–402.
Copyright (c) 2026 Arquivos do Mudi
This work is licensed under a Creative Commons Attribution 4.0 International License.
DECLARAÇÃO DE ORIGINALIDADE E DIREITOS AUTORAIS
Declaro que o presente artigo é original, não tendo sido submetido à publicação em qualquer outro periódico nacional ou internacional, quer seja em parte ou em sua totalidade.
Os direitos autorais pertencem exclusivamente aos autores. Os direitos de licenciamento utilizados pelo periódico é a licença Creative Commons Attribution 4.0 (CC BY ): são permitidos o acompartilhamento (cópia e distribuição do material em qualqer meio ou formato) e adaptação (remix, transformação e criação de material a partir do conteúdo assim licenciado para quaisquer fins, inclusive comerciais.
Recomenda-se a leitura desse link para maiores informações sobre o tema: fornecimento de créditos e referências de forma correta, entre outros detalhes cruciais para uso adequado do material licenciado.
